huberman glp 1 Effects of Stopping GLP-1 Drugs Explained by Dr. Mark Hyman Andrew Huberman explains why GLP-1

Semaglutide is currently FDA-approved under three brand names: Ozempic for type 2 diabetes management Wegovy for chronic weight management in obesity Rybelsus an oral tablet formulation for type 2 diabetes Clinical studies have shown Semaglutide to be highly effective in reducing body weight and improving cardiometabolic health

SELECT - 20% reduction in major adverse cardiovascular events at 2.4 mg

The role of dietary protein in optimizing muscle mass, function and health outcomes in older individuals

Nuts and seeds almonds, black sesame, red beans, and soybeans

Additionally, they offer no proven benefit beyond tirzepatide's substantial weight loss effects and may worsen anxiety or sleep disturbances

bone metabolism